Radiation oncologist Dr. Richard Crownover, neurosurgeon Dr. Analiz Rodriguez and their care team at the University of Arkansas for Medical Sciences (UAMS) have performed the state’s first application of GammaTile Therapy.
GammaTile Therapy, marketed by GT Medical Technologies and also known as surgically targeted radiation therapy (STaRT), is designed to delay brain tumor recurrence. It consists of a 3D-collagen tile embedded with a cesium radiation source. GammaTile is placed in the tumor cavity at the time of surgery so that it immediately begins to target residual tumor cells with radiation while limiting the impact on healthy brain tissue.
“GammaTile Therapy is a welcome addition to our treatment options available to brain tumor patients,” said Rodriguez, who serves as the director of Neurosurgical Oncology at UAMS. “Small wafers are implanted around the tumor site when it’s removed and are slowly absorbed by the tissue as the radiation treatment is delivered.”
GammaTile Therapy, approved by the Food and Drug Administration in 2019, is the only radiation therapy specifically designed for use in the brain and offers advantages for patients undergoing surgery for brain tumors. GammaTile begins targeting residual tumor cells immediately at the time of tumor removal surgery while avoiding damage to healthy brain tissue. In addition, the burden of radiation treatment is reduced. Patients receive treatment while going about their daily lives and require no additional trips to the hospital or clinic for radiation therapy.